本文選題：腦心綜合征 + 參松養(yǎng)心膠囊�。� 參考：《中國藥房》2017年33期

【摘要】：目的:觀察參松養(yǎng)心膠囊聯(lián)合依達拉奉治療腦血管疾病并發(fā)腦心綜合征(CCS)的療效和安全性。方法:128例腦血管疾病并發(fā)CCS患者隨機分為對照組(64例)和觀察組(64例)。對照組患者給予常規(guī)治療,觀察組患者在對照組治療的基礎上給予參松養(yǎng)心膠囊1.6 g,每日3次,口服+依達拉奉注射液30 mg,加入0.9%氯化鈉溶液250 mL中,靜脈滴注,每日2次。兩組療程均為10 d。觀察兩組患者的臨床療效,治療前后血清丙二醛(MDA)、超氧化物歧化酶(SOD)、兒茶酚胺[去甲腎上腺素(NE)、腎上腺素(E)、多巴胺(DA)]水平、肌鈣蛋白I(cTnⅠ)、美國國立衛(wèi)生研究院卒中量表評分(NIHSS),分析cTnⅠ水平與NIHSS評分相關性,并記錄不良反應發(fā)生情況。結果:觀察組患者神經(jīng)系統(tǒng)、心電圖總有效率均顯著高于對照組,差異均有統(tǒng)計學意義(P0.05)。治療前,兩組患者血清MDA、SOD、NE、E、DA、cTnⅠ水平、NIHSS評分比較,差異均無統(tǒng)計學意義(P0.05)。治療后,兩組患者血清MDA、NE、E、DA、cTnⅠ水平、NIHSS評分均顯著低于同組治療前,且觀察組顯著低于對照組;兩組患者血清SOD水平均顯著高于同組治療前,且觀察組顯著高于對照組,差異均有統(tǒng)計學意義(P0.05)。cTnⅠ水平與NIHSS評分呈正相關(r=0.956,P=0.001)。兩組患者不良反應發(fā)生率比較,差異無統(tǒng)計學意義(P0.05)。結論:在常規(guī)治療的基礎上,參松養(yǎng)心膠囊聯(lián)合依達拉奉可顯著提高腦血管疾病并發(fā)CCS患者的療效,改善兒茶酚胺、MDA、SOD水平,且未增加不良反應的發(fā)生。
[Abstract]:Objective: to observe the efficacy and safety of Shensong Yangxin capsule combined with Edaravone in the treatment of cerebrovascular diseases complicated with cerebral heart syndrome (CCS). Methods 128 cases of cerebrovascular disease complicated with CCS were randomly divided into control group (n = 64) and observation group (n = 64). The patients in the control group were given routine treatment, and the patients in the observation group were given Shensong Yangxin capsule 1.6 g, 3 times a day, 30 mg of Edaravone injection, added 0.9% sodium chloride solution 250 mL, intravenous drip twice a day. The course of treatment in both groups was 10 days. The clinical efficacy of the two groups was observed. The levels of serum malondialdehyde (MDA), superoxide dismutase (SOD), catecholamine (NE), epinephrine (epinephrine), dopamine (DA) before and after treatment were observed. Cardiac troponin (I(cTn 鈪，

本文編號：1788130